YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

Studies show that people with psoriasis, especially those with severe cases, have a much higher risk of heart disease than ...

Omni Medique is a specialist regenerative hair and scalp clinic providing non-surgical hair restoration and scalp treatment ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

Symptoms, lesion locations, and morphology are among the features clinicians may use to distinguish hand eczema from hand psoriasis in patients.

Among 25 different measures of adiposity, abdominal fat was significantly associated with a risk for psoriasis. Among 25 ...

Dr. Jason Rivers, MD, FRCPC, discusses psoriasis symptoms and treatments. Hawaii's governor signs new hotel tax legislation to help cope with climate change ...